Jubilant, J&J in Discovery Pact

Jubilant Discovery Services, a Jubilant Life Sciences Company, has entered into a drug discovery alliance with Janssen Pharmaceutica N.V., Beerse, Belgium. The alliance is set to span an initial period of three years and will focus on multiple targets in the area of neuroscience.

Janssen will transfer ongoing efforts on selected drug discovery targets to Jubilant. Jubilant will carry out research services and deliver preclinical candidates to Janssen for possible further development and commercialization. In addition to research funding, Jubilant may also be eligible to receive milestones and royalties should Janssen successfully develop and commercialize the candidates.

Commenting on this development, Sri Mosur, Jubilant’s chief executive officer and president, Global Drug Discovery & Development, remarked, “The collaboration will utilize Jubilant’s global research network to include our new research facility in the U.S. focused in the area of neuroscience, in addition to our India-based research centers. We look forward to enhancing the research and development efforts at Janssen through this unique and creative alliance in these dynamic times in the industry.”